Clinical Trials Logo

Clinical Trial Summary

Patients who suffer Alcohol Use Disorder (AUD) have a 30-80% incidence of thiamine deficiency causing Wernicke's Encephalopathy (WE).

Intravenous (IV) thiamine replacement is standard practice in the treatment of alcoholic patients presenting to the Accident & Emergency (A&E) department, however routine co-supplementation with magnesium (administered IV as magnesium sulphate ), which is required as a co-factor for thiamine in some metabolic processes, e. g. on the activity of the enzyme transketolase in red blood cells, is not routine practice in the treatment of these patients. Without correction of concomitant magnesium deficiency there may be impaired utilisation of thiamine resulting in a failure to treat WE.

This study is designed to determine if administration of magnesium to AUD patients affects red cell transketolasae and serum lactate concentrations by itself, or only acts to increase the effect of thiamine on the activity of this enzyme.


Clinical Trial Description

This is a 3- arm randomised, open label, controlled study in a cohort of alcoholic patients admitted through A&E. Patients will be randomised to concurrent infusion of one of the following:

- Arm 1: IV thiamine

- Arm 2: IV magnesium sulphate followed by delayed IV thiamine

- Arm 3: IV thiamine and IV magnesium sulphate Thiamine will be administered as IV Pabrinex, a compound preparation which also contains B vitamins and vitamin C. Administration of IV Pabrinex is standard care in this patient group and magnesium sulphate is routinely co-administered at Glasgow Royal Infirmary. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03466528
Study type Interventional
Source Glasgow Royal Infirmary
Contact
Status Completed
Phase Phase 2/Phase 3
Start date December 16, 2016
Completion date June 19, 2018

See also
  Status Clinical Trial Phase
Recruiting NCT03916939 - Osteopathic Treatment to Alcohol Withdrawal Syndrome N/A
Completed NCT04858490 - Remote Treatment of Alcohol Withdrawal N/A
Not yet recruiting NCT04997330 - Evaluation of Bilateral HF-rTMS on Abstinence in Alcohol Use Disorder Patients With Executive Dysfunction N/A
Recruiting NCT04876443 - Impact of COVID-19 Outbreak on the Alcohol Consumption in Patients With Alcohol-related Liver Disease (ICoLD)
Completed NCT05131334 - Auricular Vagal Stimulation in Alcohol Craving N/A
Completed NCT02349477 - Gabapentin for Alcohol Relapse Prevention Phase 2
Terminated NCT01937364 - Preventing Alcohol Withdrawal With Oral Baclofen Phase 2
Completed NCT05393544 - Digitally Assisted Recovery Coach N/A
Completed NCT00523185 - A Comparison of Lorazepam and Diazepam in the Treatment of Alcohol Withdrawal N/A
Completed NCT01573052 - Gabapentin vs Chlordiazepoxide for Ambulatory Alcohol Withdrawal Phase 4
Enrolling by invitation NCT06173973 - Effects of Ketone Supplementation on Acute Alcohol Withdrawal Phase 2/Phase 3
Active, not recruiting NCT03737864 - NCARE, Transition to Recovery N/A
Recruiting NCT03878225 - Does a Ketogenic Dietary Supplement Reduce Alcohol Withdrawal Symptoms in Humans? N/A
Terminated NCT03586089 - Phenobarbital for Severe Acute Alcohol Withdrawal Syndrome N/A
Recruiting NCT04156464 - Phenobarbital vs Ativan for Alcohol Withdrawal in the Intensive Care Unit Phase 4
Completed NCT02202148 - Liver Stiffness Measurement in Alcohol-dependent Subjects in Relation to Abstinence After Withdrawal N/A
Completed NCT02251912 - Oxytocin Treatment of Alcohol Dependence Phase 2
Completed NCT01212185 - Oxytocin Treatment of Alcohol Withdrawal Phase 1
Recruiting NCT04793685 - Prazosin for Alcohol Use Disorder With Withdrawal Symptoms Phase 1/Phase 2
Withdrawn NCT04159909 - Using Transcutaneous Auricular Vagus Nerve Stimulation to Treat Acute Alcohol Withdrawal N/A